Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

WHO, UNICEF publish plan to reduce childhood diarrhea deaths

The WHO and UNICEF have released a seven-point treatment and prevention plan to reduce the number of children around the world who die from diarrhea, the BBC reports (10/14). BMJ News writes, "Every year 1.5 million children aged under 5 years die from diarrhoea, more than 80% of them in Africa and south Asia" (Zarocostas, 10/14).

19 Oct 2009

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

CVS Caremark's seasonal flu shot clinics to run through October 22

CVS/pharmacy announced today that its seasonal flu shot clinics will run through October 22, in light of manufacturer delays in delivery of seasonal flu vaccine affecting all health care providers. However, MinuteClinic will continue to administer seasonal flu vaccines at its 500 locations in 25 states throughout the flu season with the supply of vaccine replenished as frequently as possible.

19 Oct 2009

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

19 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

14 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

AP examines H1N1 surveillance by U.S., WHO

The Associated Press examines how the decision by U.S. health officials to stop counting new cases of H1N1 (swine flu) in July has complicated the government's ability to assess groups particularly hard hit by the virus.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

BioDelivery Sciences International, Inc. announced that its commercial partner Meda will launch the FDA-approved ONSOLIS (fentanyl buccal soluble film) next week for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

8 Oct 2009

Precautionary measures being taken at Texas hospitals for combating flu

Precautionary measures are being taken at hospital ERs across Texas in order to deal with record numbers of flu cases this season. According to a recent article on NBCDFW.com, hospital emergency rooms, including the one at Children's Medical Center of Dallas, are screening visitors for flu symptoms and not allowing children under 12 to be in the patient areas unless they are being treated.

8 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

Vomiting News and Research

Further Reading

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

WHO, UNICEF publish plan to reduce childhood diarrhea deaths

FDA grants marketing approval for Elitek

CVS Caremark's seasonal flu shot clinics to run through October 22

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

FDA approves Berinert for the treatment of hereditary angioedema

AP examines H1N1 surveillance by U.S., WHO

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

Precautionary measures being taken at Texas hospitals for combating flu

FDA approves Daiichi Sankyo's sNDA for Welchol

Shire publishes efficacy study results of FOSRENOL and Renagel

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News